12-month effectiveness and safety data from SmartFire study presented at 2025 EHRA Congress by Johnson & Johnson MedTech.
Latest heart disease treatment advancements with Impella highlighted at ACC.25 by Johnson & Johnson MedTech.
European Commission approves Abrysvo to protect adults 18-59 against RSV lower respiratory tract disease.